18
total announcements
500288.BO · 15 min delayed
Morepen Laboratories Ltd
Morepen Laboratories Ltd has published a newspaper notice for the completion of dispatch of the notice of its 41st Annual General Meeting and the Annual Report for the financial year 2025-26.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has dispatched letters to unregistered members with a weblink to access the Annual Report for 2025-26. The company has also announced the 41st AGM on September 26, 2026, and proposed a final dividend of ₹ 0.20 per equity share.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 26, 2026, through video conferencing. The AGM will consider the adoption of financial statements, declaration of final dividend, appointment of a director, and other business.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has released its Annual Report for the financial year 2025-26, along with the notice of its 41st Annual General Meeting scheduled for September 26, 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has published a newspaper notice regarding its 41st Annual General Meeting, dividend, and record date. The notice is in accordance with Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's website has the notice available for public access.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has informed that its wholly owned subsidiary, Morepen RX Limited, has allotted 2,00,00,000 equity shares to the company at par, aggregating to Rs. 20,00,00,000, to strengthen its capital base and support its business operations.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors on August 4, 2026. The results are available on the company's website and have been published in the Financial Express (English) and Jansatta (Hindi) newspapers on August 5, 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has released a monitoring agency report for the quarter ended June 30, 2026, as per SEBI regulations, detailing the utilization of proceeds from its qualified institutions placement issue.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced the outcome of its Board meeting, which includes the approval of un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, and the record date for the final dividend for the financial year ended March 31, 2026. The company has also announced the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years, subject to member approval at the 41st Annual General Meeting on September 26, 2026.
Morepen Laboratories Ltd
The Board of Directors of Morepen Laboratories Ltd has approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further period of three years, effective from October 20, 2026. The company has also announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and has fixed a record date for the final dividend for the financial year ended March 31, 2026. Additionally, the company has sought approval from its members for the extension of the approved timeline for hiving off its Medical Devices Business into a subsidiary company.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced the record date for payment of final dividend for the financial year ended 31st March 2026, subject to approval at the 41st Annual General Meeting. The company has also approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further period of three years. Additionally, the company has announced the notice of the 41st AGM to be held on 26th September 2026.
Morepen Laboratories Ltd
Morepen Laboratories Ltd reported its highest-ever quarterly revenue and earnings in Q1 FY27, with EBITDA growing by 207% and PAT by 394%. The company's CDMO mandate entered full scale commercialization phase, with Rs. 58 Cr worth of commercial CDMO dispatches already completed during the quarter.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has released its Q1 FY 27 Investor Presentation, highlighting a 34% YoY increase in revenue, 207% YoY increase in EBITDA, and 394% YoY increase in PAT. The company attributes this performance to operational execution and commercial validation of its Morepen 2.0 strategy.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced its Q1 FY 27 Financial Results, with the Board of Directors approving the un-audited standalone & consolidated financial results for the quarter ended June 30, 2026. The company has also declared a record date for determining members eligible to receive final dividend for the financial year ended March 31, 2026, subject to approval at the 41st Annual General Meeting. Additionally, the Board has approved the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years, subject to approval at the 41st AGM.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has announced its Q1 FY 27 financial results, with the Board of Directors considering and approving the un-audited standalone & consolidated financial results for the quarter ended June 30, 2026. The company has also announced a record date for the final dividend for the financial year ended March 31, 2026, and the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director for a further period of three years.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/08/2026 to consider and approve financial results for Q-1 FY27. The trading window will remain closed till 48 hours after the declaration of financial results.
Morepen Laboratories Ltd
Morepen Laboratories Ltd has changed the name of its wholly owned subsidiary company from Morepen Labs - FZCO to Morepen Labs FZE, following the migration of the company's subsidiary from the International Free Zone Authority to the Jebel Ali Free Zone.